XML 19 R12.htm IDEA: XBRL DOCUMENT v3.24.3
Cash, Cash Equivalents and Marketable Securities
9 Months Ended
Sep. 30, 2024
Marketable Securities [Abstract]  
Cash, Cash Equivalents, and Marketable Securities

4. Cash, Cash Equivalents and Marketable Securities

 

Available-for-sale marketable securities were as follows (in thousands):

 

 

September 30, 2024

 

 

Amortized
Cost

 

 

Unrealized
Gains

 

 

Unrealized
Losses

 

 

Fair Value

 

Government agency

$

512,938

 

 

$

1,898

 

 

$

 

 

$

514,836

 

Total

$

512,938

 

 

$

1,898

 

 

$

 

 

$

514,836

 

 

 

 

 

 

 

 

 

 

 

 

 

 

December 31, 2023

 

 

Amortized
Cost

 

 

Unrealized
Gains

 

 

Unrealized
Losses

 

 

Fair Value

 

Commercial paper

$

26,752

 

 

$

 

 

$

(15

)

 

$

26,737

 

Corporate debt

 

5,988

 

 

 

 

 

 

(7

)

 

 

5,982

 

Government agency

 

301,315

 

 

 

584

 

 

 

(16

)

 

 

301,884

 

Total

$

334,056

 

 

$

584

 

 

$

(38

)

 

$

334,602

 

 

The fair value of available-for-sale marketable securities by contractual maturity as of September 30, 2024 and December 31, 2023 were as follows (in thousands):

 

 

September 30, 2024

 

 

December 31, 2023

 

Due in 1 year or less

$

412,406

 

 

$

307,434

 

Due in 1 - 2 years

 

102,430

 

 

 

27,168

 

Total

$

514,836

 

 

$

334,602

 

 

The Company had 2 and 8 securities in an unrealized loss position as of September 30, 2024 and December 31, 2023, respectively. All securities in an unrealized loss position as of September 30, 2024 and December 31, 2023 had been in a loss position for less than twelve months. Unrealized losses on available-for-sale marketable securities as of September 30, 2024 and December 31, 2023 were not significant and were primarily due to changes in interest rates, including market credit spreads, and not due to increased credit risks associated with specific securities. Accordingly, no allowance for credit losses related to the Company’s available-for-sale marketable securities was recorded for the nine months ended September 30, 2024 and for the year ended December 31, 2023. The Company does not intend to sell these securities and it is unlikely that the Company will be required to sell the investments before recovery of their amortized cost bases, which may be at maturity.

 

As of September 30, 2024 and December 31, 2023, the Company recognized $3.4 million and $1.4 million, respectively, of accrued interest receivable from available-for-sale securities within prepaid expenses and other current assets on the condensed consolidated balance sheets.

 

The following table reconciles cash, cash equivalents and restricted cash per the condensed consolidated balance sheets to the condensed consolidated statements of cash flows (in thousands):

 

 

 

 

 

 

 

 

September 30,

 

 

2024

 

 

2023

 

Cash and cash equivalents

$

161,846

 

 

$

126,119

 

Restricted cash

 

2,626

 

 

 

4,929

 

Total

$

164,472

 

 

$

131,048